- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
PRE-EMPTIVE ADMINISTRATION OF FIBRINOGEN CONCENTRATE CONTRIBUTES TO IMPROVED PROGMOSIS IN PATIENTS WITH SEVERE TRAUMA
-
- Yamamoto Koji
- Department of Transfusion Medicine and Cell Therapy, Saitama Medical Center, Saitama Medical University
-
- Yamaguchi Atsushi
- Department of Emergency and Critical Care Medicine, Saitama Medical Center, Saitama Medical University
-
- Sawano Makoto
- Department of Emergency and Critical Care Medicine, Saitama Medical Center, Saitama Medical University
-
- Matsuda Masaki
- Department of Emergency and Critical Care Medicine, Saitama Medical Center, Saitama Medical University
-
- Anan Masahiro
- Department of Transfusion Medicine and Cell Therapy, Saitama Medical Center, Saitama Medical University
-
- Inokuchi Koichi
- Department of Emergency and Critical Care Medicine, Saitama Medical Center, Saitama Medical University
-
- Sugiyama Satoru
- Department of Emergency and Critical Care Medicine, Saitama Medical Center, Saitama Medical University
Bibliographic Information
- Other Title
-
- 重症外傷患者に対するフィブリノゲン製剤の先制投与は予後の改善に寄与する
- Pre-emptive administration of fibrinogen concentrate contributes to improved prognosis in patients with severe trauma
Search this article
Description
<p>背景と目的:外傷患者の急性期には凝固障害を認めることが多く,その程度は患者の生命予後を左右する.当院の高度救命救急センターでは,外傷患者の凝固障害,特に高度な低フィブリノゲン血症をすみやかに改善させる目的で,積極的にフィブリノゲン製剤の投与を行ってきた.その治療の実際と,同製剤の投与群と非投与群間で行った輸血量および生命予後の比較検討(症例対照研究)結果を報告する.方法:フィブリノゲン製剤投与の有無および投与基準の違いによって症例を3群に分けた.A群,フィブリノゲン製剤未使用;B群,受診時のフィブリノゲン値と外傷重症度を見た上でフィブリノゲン製剤3gを投与;C群,患者搬送前の情報(外傷重症度,出血状況)から判断し,搬送時ただちにフィブリノゲン製剤3gを投与.外傷重症度スコア≧26の症例における輸血量および生命予後について3群間で比較検討を行った.結果:3群間の輸血量には有意差を認めなかった.受診30日後の総生存率(搬送時の心肺停止症例を除く)はC群で有意に高く(p<0.05),搬送後48時間以内の急性期死亡率はC群で有意に低かった(p=0.005).さらに,きわめて重篤とされる外傷重症度スコア≧41群での死亡率も,C群で有意に低かった(p=0.02).結論:重症外傷症例においては,フィブリノゲン製剤の先制投与が急性期死亡率の低下に貢献し,結果として高い生存退院率をもたらす可能性が示唆された.</p>
Journal
-
- Japanese Journal of Transfusion and Cell Therapy
-
Japanese Journal of Transfusion and Cell Therapy 63 (2), 135-139, 2017
The Japan Society of Transfusion Medicine and Cell Therapy